HomeAI · summaries
Storia in 3 fonti
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
koreaherald.com
SK Biopharm strikes $800m deal for epilepsy drug from Biohaven
SK Biopharmaceuticals is staking nearly $800 million on rights to an epilepsy treatment from US biotech firm Biohaven, the company said Wednesday. In a regulato
- ·
morningstar.com
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead…
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
